Each tablet contains 0.75 mg levonorgestrel.
Excipients/Inactive Ingredients: Colloidal silicon dioxide, magnesium stearate, potato starch, talc, maize starch, lactose.
Levonorgestrel is a progestogen inhibiting the implantation of the ovum into the endometrium, stimulating the motility of the oviduct and increasing the viscosity of the cervical mucus.
Postinor-2 tablet is an emergency contraceptive preparation that can prevent contraception if it is taken within 72 hours following unprotected intercourse.
The administration of Postinor-2 as an emergency contraceptive is recommended in the following cases:
If no contraceptive measure of any kind was taken during intercourse; If the applied contraceptive measure cannot be considered reliable, i.e. tear or slip inappropriate use of condom; disposition or tear or premature removal of diaphragm or pessary; unsuccessfully interrupted coitus; erroneous calculation of fertile days in case of periodic abstinence; in case of IUD loss or removal; omitting the ingestion of 3 or more hormonal contraceptive tablets to be taken regularly; rape.
One Postinor-2 tablet should be ingested within 72 hours following intercourse and another one 12 hours after taking the first tablet.
According to data of clinical studies, it is advisable to take the first tablet within 48 hours (but not later than 72 hours) after intercourse, since the efficacy of the preparation decreases if more than 48 hours elapse between intercourse and drug ingestion. Postinor-2 tablet may be used at any time within the menstrual cycle.
If vomiting occurs within 2 hours after drug intake, the dose must be repeated.
No more than 4 tablets may be taken per month.
Except for existing pregnancy, there are no other absolute medical contraindications for the administration of Postinor-2 tablet. In case of vaginal bleeding of unknown origin, hepatic and biliary disease, history of gestational jaundice, breast, ovarian or uterine carcinoma, it should be administered after careful consideration of the risk/benefit ratio (unwanted pregnancy/abortion).
Use with utmost care in case of asthma, heart failure, hypertension, migraine, epilepsy, renal impairment, diabetes mellitus, hyperlipidaemia, depression and in case of existing or former thrombophlebitis, thromboembolic diseases or stroke.
The preparation may be used exclusively in the above mentioned emergency cases; it is not appropriate for regular use.
For emergency post-coital use only. Not for routine contraceptive use. Pregnancy should be excluded before use.
Repeated use may cause disruption of normal menstrual cycle and irregular bleeding.
Except for existing pregnancy, there are no other absolute medical contraindications for the administration of Postinor-2 tablet.
It should be administered after careful consideration of the risk/benefit ratio (unwanted pregnancy/abortion).
Pregnancy should be excluded before use.
Nausea: It occurs in approximately 25% of users.
Vomiting: In 5%.
Bleeding Disturbances: In some cases, 2-3 days following tablet ingestion breakthrough or withdrawal bleeding may occur that generally ceases spontaneously. In the majority of cases, the next period starts as expected or somewhat earlier. If the period is more than 7 days late, it is recommended to perform a pregnancy test.
In case of prolonged or heavy bleeding, gynaecological examination is advised.
Other Side Effects: Breast tenderness, headache, dizziness, fatigue.
Concomitant use of ampicillin, rifampicine, chloramphenicol, neomycin, sulphonamides, tetracyclines, barbiturates and phenylbutazone may reduce the contraceptive effect.
G03AC03 - levonorgestrel ; Belongs to the class of progestogens. Used as systemic contraceptives.